相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study
Alessandra Iurlo et al.
FRONTIERS IN ONCOLOGY (2022)
Cancer patients' perspective on shared decision-making and decision aids in oncology
Lena Josfeld et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands
Genevieve I. C. G. Ector et al.
LEUKEMIA (2021)
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
Kazunori Murai et al.
Lancet Haematology (2021)
OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Developing Symptom Lists for People with Cancer Treated with Targeted Therapies
Samantha C. Sodergren et al.
TARGETED ONCOLOGY (2021)
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
Kiran Naqvi et al.
CANCER (2020)
The Medication Adherence Report Scale: A measurement tool for eliciting patients' reports of nonadherence
Amy Hai Yan Chan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study
Emilie Cayssials et al.
CANCER (2020)
The Perception of Shared Decision-Making in Hematology by Patients and Physicians Seems Satisfactory, but Important Steps are Still Ahead of Us
Paulus A. F. Geerts et al.
HEMASPHERE (2020)
Decisional involvement and information preferences of patients with hematologic malignancies
Kah Poh Loh et al.
BLOOD ADVANCES (2020)
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
Timothy P. Hughes et al.
HAEMATOLOGICA (2019)
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
Richard E. Clark et al.
LANCET HAEMATOLOGY (2019)
The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission
Claire Andrews et al.
LEUKEMIA & LYMPHOMA (2019)
Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
Artur C. Fassoni et al.
HAEMATOLOGICA (2018)
Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
Artur C. Fassoni et al.
HAEMATOLOGICA (2018)
Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response
Francisco Cervantes et al.
ANNALS OF HEMATOLOGY (2017)
Shared decision-making and providing information among newly diagnosed patients with hematological malignancies and their informal caregivers: Not one-size-fits-all
J. A. J. Rood et al.
PSYCHO-ONCOLOGY (2017)
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
Richard E. Clark et al.
LANCET HAEMATOLOGY (2017)
Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012
Noortje Thielen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The psychometric properties of Observer OPTION5, an observer measure of shared decision making
Paul J. Barr et al.
PATIENT EDUCATION AND COUNSELING (2015)
The iMTA Productivity Cost Questionnaire A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses
Clazien Bouwmans et al.
VALUE IN HEALTH (2015)
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Peter Valent et al.
BLOOD (2015)
Dutch Translation and Psychometric Testing of the 9-Item Shared Decision Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician Version (SDM-Q-Doc) in Primary and Secondary Care
Sumayah Rodenburg-Vandenbussche et al.
PLOS ONE (2015)
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase
Annie Guerin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24
Fabio Efficace et al.
QUALITY OF LIFE RESEARCH (2014)
Decision aids for people facing health treatment or screening decisions
Dawn Stacey et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
An-Wen Chan et al.
ANNALS OF INTERNAL MEDICINE (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Using a 'talk' model of shared decision making to propose an observation-based measure: Observer OPTION5 Item
Glyn Elwyn et al.
PATIENT EDUCATION AND COUNSELING (2013)
Intolerance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Definitions and Clinical Implications
Javier Pinilla-Ibarz et al.
CANCER (2011)
Validation of a decision regret scale
JC Brehaut et al.
MEDICAL DECISION MAKING (2003)
分享论文
